Search results for "absorption."

showing 10 items of 2682 documents

Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's dise…

2018

[EN] Effective treatment of Parkinson's disease (PD) involves administration of therapeutic agents with complementary mechanisms of action in order to replenish, sustain or substitute endogenous dopamine. The objective of this study was to investigate anodal co-iontophoresis of pramipexole (PRAM; dopamine agonist) and rasagiline (RAS; MAO-B inhibitor) in vitro and in vivo. Passive permeation of PRAM and RAS (20 mM each) across porcine skin after 6 h was 15.7 +/- 1.9 and 16.0 +/- 2.9 mu g/cm(2), respectively. Co-iontophoresis at 0.15, 0.3 and 0.5 mA/cm(2) resulted in statistically significant increases in delivery of PRAM and RAS; at 0.5 mA/cm(2), cumulative permeation of PRAM and RAS was 61…

MaleParkinson's diseaseSwineChemistry PharmaceuticalSkin AbsorptionPharmaceutical SciencePharmacologyAdministration Cutaneous030226 pharmacology & pharmacyDopamine agonistPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePramipexolePharmacokineticsIn vivomedicineAnimalsHumansBenzothiazolesMAO-B inhibitorRats WistarTransdermalSkinRasagilinePramipexoleIontophoresisDopamine agonistPatient complianceParkinson DiseaseGeneral MedicineIontophoresismedicine.diseaseRatschemistryIndansPolypharmacyElectroosmosisTransdermal030217 neurology & neurosurgeryBiotechnologymedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Growth charts of Down syndrome in Sicily: evaluation of 382 children 0-14 years of age.

2005

We present the results of a study performed on a Sicilian population of children with Down syndrome (DS) 0–14 years of age, observed between 1977 and 1988. Data from the present report concern 382 subjects with nonmosaic 21 trisomy, including 239 males (62.6%) and 143 females (37.4%). We excluded all DS children observed in the same period with associated pathology (congenital heart defects, gastrointestinal malformations, malabsorption, hypothyroidism, and thalassemia). Overall, 1,464 measurements were performed of length or height, weight, and head circumference. Means and standard deviation (SD) were calculated for all of these parameters. Our data confirm a trend toward a progressive im…

MalePediatricsmedicine.medical_specialtyDown syndromeMalabsorptionAdolescentThalassemiaPopulationAneuploidyGrowthBiologymedicineHumanseducationChildSicilyGenetics (clinical)Geneticseducation.field_of_studyInfant NewbornInfantmedicine.diseaseBody HeightEl NiñoChild PreschoolFemaleDown SyndromeTrisomyGastrointestinal malformationsAmerican journal of medical genetics. Supplement
researchProduct

Steatocrit test: Normal range and physiological variations in infants

1990

In order to define the normal values of steatocrit during the first 3 months of life and the normal correlation between fecal fat content and steatocrit values, 60 full-term healthy unweaned infants (30 bottle-fed, 15 breast-fed, and 15 mixed-fed) were studied. The steatocrit micromethod was performed in these babies at 7, 14, 21, 28, 45, and 90 days after birth. Steatorrhea often occurs during the first month and then decreases, as shown by the fall in the steatocrit curve from 7th to 28th day in our subjects; at 45 days, few babies have steatorrhea. The 90th percentile profile of steatocrit values shows a value of 25% at the first week of life and a value of 13% at the fourth week. After …

MalePercentileFat contentPhysiologyNormal valuesFat absorptionFatsFecesReference ValuesAnimalsHumansMedicineNormal rangebusiness.industryFeces analysisInfant NewbornGastroenterologyInfantDietRatsSteatorrheaCeliac DiseaseReference valuesPediatrics Perinatology and Child HealthFemalemedicine.symptombusiness
researchProduct

The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs.

2018

Pharmaceutical excipients that may affect gastrointestinal (GI) drug absorption are called critical pharmaceutical excipients, or absorption-modifying excipients (AMEs) if they act by altering the integrity of the intestinal epithelial cell membrane. Some of these excipients increase intestinal permeability, and subsequently the absorption and bioavailability of the drug. This could have implications for both the assessment of bioequivalence and the efficacy of the absorption-enhancing drug delivery system. The absorption-enhancing effects of AMEs with different mechanisms (chitosan, sodium caprate, sodium dodecyl sulfate (SDS)) have previously been evaluated in the rat single-pass intestin…

MalePharmaceutical ScienceExcipientBiological Availability02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyIntestinal absorptionPermeabilityExcipients03 medical and health sciences0302 clinical medicineDogsIn vivomedicineAnimalsPharmaceutical sciencesIntestinal MucosaChitosanIntestinal permeabilityChemistrySodium Dodecyl Sulfate021001 nanoscience & nanotechnologymedicine.diseaseBioavailabilityRatsIntestinesIntestinal AbsorptionPharmaceutical PreparationsDrug delivery0210 nano-technologyDecanoic Acidsmedicine.drugInternational journal of pharmaceutics
researchProduct

Non-linear Intestinal Absorption Kinetics of Cefadroxil in the Rat

1989

Abstract Absorption of Cefadroxil in a selective intestinal absorption area (the proximal third of the small intestine) of the anaesthetized rat, at seven initial perfusion concentrations, ranging from 0·01 to 10·0 mg mL−1, is shown to be a non-linear transport mechanism. With the aid of computer-fitting procedures based on differential and integrated forms of Michaelis-Menten equation, Vm and Km values of 36·7–37·3 mg h−1 and 12·0–13·0 mg, respectively, were found. The statistical parameters were better than those obtained both for first-order and for combined Michaelis-Menten and first-order kinetics. There is no evidence for substantial passive diffusion processes. The results reported h…

MalePharmacologyAbsorption (pharmacology)ChromatographyChemistryDiffusionKineticsCefadroxilPharmaceutical ScienceRats Inbred StrainsIntestinal absorptionSmall intestineRatsPerfusionmedicine.anatomical_structureIntestinal AbsorptionPharmacokineticsBiochemistryIntestine SmallCefadroxilmedicineAnimalsPerfusionmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Use of nonlinear mixed effect modeling for the intestinal absorption data: application to ritonavir in the rat.

2005

The aim of this study is to investigate in situ the mechanisms involved in the gastrointestinal absorption of ritonavir in the rat, as an animal model for preclinical studies of anti-HIV agents in vivo. Four ritonavir solutions (40, 27, 13 and 7 microM) in the presence of 1% dimethylsulfoxide (DMSO) were perfused in the small intestine of anaesthetised rats. Effects of DMSO on the intestinal permeability were investigated using solutions containing antipyrine 1.33 mM and ritonavir 7 microM with and without 1% of DMSO. Antipyrine and ritonavir transport was not modified in the presence of 1% of DMSO. The population pharmacokinetic parameters of the ritonavir intestinal transport were obtaine…

MalePopulationPharmaceutical ScienceAbsorption (skin)PharmacologyIntestinal absorptionPharmacokineticsimmune system diseasesIn vivoIntestine SmallmedicineAnimalsHumansDimethyl SulfoxideRats Wistareducationeducation.field_of_studyIntestinal permeabilityRitonavirChemistryvirus diseasesGeneral MedicineHIV Protease Inhibitorsmedicine.diseaseSmall intestineRatsPerfusionmedicine.anatomical_structureIntestinal AbsorptionNonlinear DynamicsSolubilityModels AnimalRitonavirBiotechnologymedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Inhibition of Protein S by Autoantibodies in Patients with Acquired Protein S Deficiency

1996

SummaryThis study was undertaken to analyze antibodies to protein S (PS) in patients with an acquired PS deficiency. Plasma from symptomatic patients with acquired (n = 14) or congenital (n = 10) PS deficiency and 10 healthy donors was screened for PS antibodies by immunoblotting and for anti-phospholipid antibodies. PS antibodies (IgG) were detected in five of the patients with acquired PS deficiency. These antibodies belonged to the G1 and G4 immunoglobulin subclasses. IgG fractions from the same 5 patients were shown to inhibit PS activity. The inhibition of PS activity by the 5 IgG fractions was shown to be time-and dose-dependent and was abolished following incubation with purified PS,…

MaleProtein S DeficiencyProtein SAbsorptionProtein Schemistry.chemical_compoundCoagulopathymedicineCardiolipinHumansAutoantibodiesDose-Response Relationship Drugbiologybusiness.industryAutoantibodyHematologymedicine.diseaseMolecular biologyBlood proteinschemistryCase-Control StudiesImmunoglobulin GImmunologyMonoclonalAntibodies Antiphospholipidbiology.proteinFemaleVitronectinAntibodybusinessThrombosis and Haemostasis
researchProduct

Bioavailability and pharmacokinetic model for ritonavir in the rat.

2007

The aim of this study is to investigate in vivo the oral bioavailability of ritonavir and to evaluate the pharmacokinetic model that best describes the plasma concentration behavior after oral and intravenous administration. Male Wistar rats were intravenously administered at 3 mg dose of pure ritonavir and oral administered at 4.6 +/- 2.5 mg of diluted Norvir. Blood samples were taken by means of the jugular vein for a 24 h period of time. An analytical high-performance liquid chromatography (HPLC) technique was developed in order to quantify ritonavir plasma concentrations. A nonlinear modeling approach was used to estimate the pharmacokinetic parameters of interest. Results showed that a…

MaleRitonavirbiologyChemistryPharmaceutical ScienceBiological AvailabilityAbsorption (skin)PharmacologyHigh-performance liquid chromatographyModels BiologicalBioavailabilityAbsorptionRatsPharmacokineticsIn vivoEnzyme inhibitormedicinebiology.proteinAnimalsRitonavirProtease inhibitor (pharmacology)Rats Wistarmedicine.drugJournal of pharmaceutical sciences
researchProduct

Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients

2010

BACKGROUND: Reducing low-density lipoprotein cholesterol (LDL-C) is the primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD). METHODS: This double blind placebo-controlled study enrolled patients 18 to 75 years of age with primary hypercholesterolemia and establishedCHDwhowere taking a stable daily dose of simvastatin 20 mg. Patients were randomized to ezetimibe/simvastatin 10/20 mg (eze/simva; n 5 56) or simvastatin 40 mg (simva; n 5 56) for 6 weeks. Percent change from baseline in LDL-C, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were assessed by use of the Student t test. The percent of patients achieving L…

MaleSimvastatinSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismCoronary DiseasePharmacologyGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawCholesterol absorption inhibitorEzetimibe; simvastatin; coronary heart diseaseNutrition and DieteticsAnticholesteremic AgentsMiddle AgedLipidCoronary heart diseaseCholesterolDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmedicine.drug_classHypercholesterolemiaPharmacotherapyDouble-Blind MethodEzetimibeInternal medicineInternal MedicinemedicineHumansTriglyceridesCholesterol absorption inhibitorAgedCholesterolbusiness.industryCholesterol HDLCholesterol absorption inhibitor; Coronary heart disease; Ezetimibe; Lipids; SimvastatinCholesterol LDLEzetimibeClinical trialchemistrySimvastatinAzetidinesEzetimibe/simvastatinbusinessJournal of Clinical Lipidology
researchProduct

Wistar rat skin as surrogate for human skin in nortriptyline hydrochloride patch studies

2009

Six different matrices were prepared containing nortriptyline hydrochloride (NTH) with hydroxypropyl-methyl-cellulose as polymer. A mixture of transdermal enhancers was included as part of the vehicle. Diffusion studies were carried out through Wistar rat full thickness skin using Franz cells. They were compared with previously determined human heat separated epidermis in order to test if this animal can be used as model for in vivo assays. A linear correlation was obtained between NTH diffusion coefficients through both skin types (r2=0.996).

MaleSkin AbsorptionPharmaceutical ScienceHuman skinNortriptylineIn Vitro TechniquesPharmacologyAdministration CutaneousDosage formIn vivoFull thickness skinAnimalsMedicineRats WistarSkinTransdermalChromatographyintegumentary systemEpidermis (botany)business.industryRatsNortriptyline HydrochlorideModels AnimalNortriptylinebusinessmedicine.drugInternational Journal of Pharmaceutics
researchProduct